United States· US:61958-1901_7bb9d232-d878-47d0-8262-abc4d06b37f7
Genvoya
A emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat product containing elvitegravir; cobicistat; emtricitabine; tenofovir alafenamide fumarate, registered in United States by Gilead Sciences, Inc.. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR18 (emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat · ATC J05AR18
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ELVITEGRAVIR; COBICISTAT; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
- Manufacturer
- Gilead Sciences, Inc.
- Country
- United States (US)
- ATC code
- J05AR18
- ATC class
- Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1161958-1901-1
- ndc11619581901130 TABLET in 1 BOTTLE, PLASTIC (61958-1901-1)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandGenvoyaParanova Oy
- CzechiaGENVOYAGilead Sciences Ireland UC, Carrigtohill
- NorwayGenvoyaAbacus Medicine A/S
- SpainGENVOYA 150mg/150mg/200mg/10mg COMPRIMIDOS RECUBIERTOS CON PELICULAGilead Sciences Ireland Unlimited Company
- SwedenGenvoya 150 mg/150 mg/200 mg/10 mg Filmdragerad tablettGilead Sciences Ireland UC
- United KingdomGenvoya 150mg/150mg/200mg/10mg tabletsGilead Sciences Ltd
- IrelandGenvoya 150 mg/150 mg/200 mg/10 mg film-coated tabletsGilead Sciences Ireland UC
- IcelandGenvoyaGilead Sciences Ireland UC*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Genvoya
- Liechtenstein · Genvoya
- Norway · Genvoya
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf5e0e86-17ec-4c86-8f3b-d987df7fed4f GET /v1/drugs/cf5e0e86-17ec-4c86-8f3b-d987df7fed4f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "150; 150; 200; 10",
"substance": "ELVITEGRAVIR; COBICISTAT; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE",
"productndc": "61958-1901",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1; mg/1; mg/1; mg/1",
"application_number": "NDA207561",
"marketing_category": "NDA"
}See everything about emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.